Sodium nitrite oral - Theravasc

Drug Profile

Sodium nitrite oral - Theravasc

Alternative Names: TV-1001; TV1001SR

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TheraVasc
  • Developer Soin Neuroscience; TheraVasc; University of Colorado at Boulder
  • Class Antidotes; Antihypertensives; Nitrites; Small molecules; Sodium compounds; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic angiopathies; Diabetic neuropathies
  • Phase I/II Vascular disorders
  • Preclinical Systemic scleroderma

Most Recent Events

  • 07 Jun 2017 Soin Neuroscience applies for Orphan drug status in Systemic scleroderma in USA
  • 07 Jun 2017 Soin Neuroscience plans a phase III trial for Systemic scleroderma in 2018
  • 02 Aug 2016 Efficacy and adverse events data from a phase II trial in Diabetic angiopathies released by TheraVasc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top